GH Research Receives FDA Clearance for Phase 3 Trial of Depression Treatment

GH Research PLC has successfully resolved the FDA clinical hold on its investigational new drug (IND) application for GH001, aimed at treating resistant depression. This clearance permits the company to move forward with planning a pivotal phase 3 trial, which is expected to commence in 2026. GH001 presents distinct advantages, including a very short psychoactive phase of 11 minutes and fewer required treatment visits compared to competitors such as SPRAVATO. Early clinical data has also shown promise for treating postpartum depression and Bipolar 2 Disorder, though investors should be aware of the associated financial risks.